news
Press release
 
October 12, 2015
Corindus Vascular Robotics and Mayo Clinic Launch Vascular Robotic Program to Research Physician Safety

WALTHAM, MA - October 12, 2015Corindus Vascular Robotics [NYSE MKT: CVRS] today announced the formation of a joint robotic-assisted percutaneous coronary intervention (PCI) research and clinical program. The program utilizes the company's CorPath® System, the first and only FDA-cleared medical device to provide robotic-assisted precision to coronary PCI procedures while protecting hospital employees from occupational radiation exposure and orthopedic stress and strain.

Mayo Clinic physicians are using robotic technology to help patients with coronary artery disease (CAD) and initiating collaborative research projects to enhance the use of robotic technology to improve patient care as well as provider safety. The research at Mayo Clinic will be led by Gurpreet S. Sandhu, M.D., Ph.D, a Mayo Clinic cardiologist, and Director, Dr. Earl Wood Cardiac Catheterization Laboratory.

In April of 2015, the Journal of the American College of Cardiology published research highlighting the occupational health hazards of working in interventional laboratories based on research conducted by investigators at Mayo Clinic. Amongst the concerns were potential musculoskeletal and back injuries to providers from wearing lead-lined protective garments in hospital catheterization laboratories.

"The occupational hazards in this field can be devastating to people. Vascular robotics provide the biggest change to cath lab procedures in 30 years and is transforming the environment by reducing radiation exposure and spinal stresses to physicians and providing robotic precision of interventional device manipulation," said David Handler, President and CEO of Corindus. "Collaboration between Corindus and leading physicians and scientists is an important and exciting step toward accelerating the progress currently being made by robotic technology in the cardiology field."

Today, interventional procedures performed in hospital cath labs are a leading source of radiation exposure for medical personnel and has been linked to the development of cataracts, cancer, and brain and thyroid diseases. The CorPath System allows interventional cardiologists to perform procedures in a protected cockpit just a few feet away from the patient bed side. Seated in this radiation-protected cockpit, the physician uses intuitive digital controls to robotically advance guidewires, angioplasty balloons and stents through coronary arteries.

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."

For additional information, visit www.corindus.com, and follow @CorindusInc.

Forward Looking Statements

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event

Examples of such statements include statements:

  • that the level of precision that can be attained using the CorPath GRX technology, combined with the potential for remote capabilities in the future, will both expand and improve how patients are treated;
  • that Corindus has entered a transformational period with a focus on expanding its reach to partner with hospitals to build robotic programs globally;
  • that the successful completion of these procedures at Fu Wai Hospital is the first step in Corindus' growth strategy within China; and that
  • the precise positioning enhancements to the CorPath platform that allows physicians to adjust guide catheters during PCI procedures may expand the use of the CorPath GRX System to more complex cases.

Media Contacts:

Corindus Vascular Robotics, Inc.

Kate Stanton
(508) 653-3335 ext. 200
kate.stanton@corindus.com

Investor Contact:

Lynn Pieper Lewis
(415) 937-5402
ir@corindus.com
 
close the window

Please complete the form below in order to download the content.








right
close the window

Please complete the form below in order to download the content.







close the window

Please fill out this brief form to subscribe to our email newsletter.





close the window

Please complete the form below and a member of our Clinical team will contact you.






close the window

Please complete the form below in order to download the content.







close the window
Thank you for subscribing to our newsletter. You will now receive email updates from Corindus.